NRAS G13D
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors (NCT07584226) | Relay Therapeutics, Inc. | 2026-03-09 |
| Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma (NCT07083479) | Elicio Therapeutics |
Track NRAS G13D automatically
Every clearance here is in the API, with alerts when new ones post.